Skin Autofluorescence Assessment of Advanced Glycation End Products in Rheumatic Diseases
- Sponsor
- Bursa City Hospital
- Study ID
- NCT07329556
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Ankylosing Spondylitis
- Connective Tissue Diseases
- Crystal Arthropathies
- Familial Mediterranean Fever (FMF )
- Psoriatic Arthritis
- Reactive Arthritis (ReA)
- Rheumatoid Arthritis (RA
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Accepted
Study Details
Rheumatic diseases are chronic inflammatory conditions that can lead to long-term tissue damage and increased cardiovascular and metabolic risk. Advanced glycation end products (AGEs) are harmful molecules that accumulate in the body over time and are known to promote inflammation and oxidative stress. Increased AGE burden has been implicated in several chronic diseases; however, its role in rheumatic diseases has not been fully clarified. This observational, cross-sectional study aims to evaluate the accumulation of AGEs in patients with various rheumatic diseases compared with healthy individuals. AGE levels will be assessed non-invasively using skin autofluorescence measurements. By comparing AGE burden between patients and healthy controls, this study seeks to improve understanding of the potential role of AGEs in the pathophysiology of rheumatic diseases and to explore their usefulness as a non-invasive biomarker in clinical practice.
Key Dates
- Start date
- Jan 15, 2026
- Status verified
- Jan 2026
- Primary completion
- Jan 15, 2027
- Completion
- Apr 15, 2027
Study Design
- Enrollment
- 300 participants (estimated)
Arms
- Arm: Rheumatic Diseases GroupPatients diagnosed with inflammatory rheumatic diseases undergoing skin autofluorescence measurement.
- Arm: Healthy Control GroupAge- and sex-matched healthy volunteers without a diagnosis of rheumatic disease.
Primary Outcome Measure
Skin Autofluorescence-Derived Advanced Glycation End Product Level [ Time Frame: Baseline (single study visit) ]
Central Contacts
- Altuğ Güner, MD+905337414088
Related Studies
- Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy ProjectRecruiting · University of California, San Diego · La Jolla, California
- A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label ExtensionPHASE3 · Enrolling By Invitation · United Therapeutics · Phoenix, Arizona
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVOPHASE1 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama
- Rheumatology Patient Registry and BiorepositoryRecruiting · Yale University · New Haven, Connecticut